Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata

Jun 16, 2026 · Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Using Partial Temporarily Idle Raised Funds for Cash ManagementJun 13
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJun 9
Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingJun 2
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary EndpointMay 8

All Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases